New Gene Mutation Test Predicts Risk of Sudden Cardiac Death
Researchers developed a gene mutation test that predicts the severity of Long QT syndrome, helping assess the risk of sudden cardiac death.
Researchers developed a gene mutation test that predicts the severity of Long QT syndrome, helping assess the risk of sudden cardiac death.
Researchers developed a genetic testing procedure that can identify patients at high risk for cardiovascular diseases.
The biomarkers may help more quickly predict cardiomyopathy in high-risk, asymptomatic childhood cancer survivors.Â
The national program will reach about 30,000 primary care providers and cardiologists, and will assess the state of LDL screenings.
Read MoreCardio Diagnostics is collaborating with Truckers Health Network, an organization providing health and wellness options to truckers.
Read MoreA new study demonstrated the benefits of routine genetic testing for patients with advanced disease from dilated cardiomyopathy (DCM).
Read MoreActive screening of patients with type 2 diabetes or COPD more than doubles new diagnoses of cardiovascular disease compared with usual care.
Read MoreCardioMetaboliQ, an at-home blood test that empowers users to support their cardiovascular and metabolic health, is available to consumers.Â
Read MoreResearchers recently employed AI to develop a protein score to predict major atherosclerotic cardiovascular disease events (ASCVD).
Read MoreA simple blood test may predict the risk of progressive heart and kidney disease in people with Type 2 diabetes and kidney disease.
Read MoreScientists may have identified a way to spot for early warning signs of cardiovascular disease via a simple saliva sample.
Read MoreThe FDA cleared the AXINON LDL-p Test System as a tool physicians can use to measure lipoproteins for those at risk of cardiovascular disease.Â
Read MoreKarius announced the inclusion of the Karius Test, a liquid biopsy test, in the 2023 Duke-ISCVID Criteria for Infective Endocarditis.
Read MoreQuidel is recalling its Triage Cardiac Panel after reports of inaccurate tests showing lower-than-expected troponin levels in samples.
Read MoreResearchers found that CoDE-ACS was able to rule out a heart attack in more than double the number of patients, with an accuracy of 99.6%.
Read MoreThe BNP control is designed to be used alongside the Acusera range of third-party controls, providing a comprehensive package.
Read MoreThe new CONNEQT Pulse is a customizable vascular biometric monitor that provides medical grade arterial heart health metrics.
Read MoreIllumina and Henry Ford Health launched a partnership to assess the impact of comprehensive genomic testing in cardiovascular disease.Â
Read More